New gene therapy SNUG01 targets ALS in first human trial

NCT ID NCT07169175

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 30 times

Summary

This early-stage study tests a new gene therapy called SNUG01 in 21 adults with ALS. The main goal is to check if it is safe and tolerable, and to see early signs of whether it might slow the disease. Participants receive the treatment via a spinal injection and are closely monitored for side effects and any changes in their condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, 350000, China

  • Massachusetts General Hospital

    Boston, Massachusetts, 02467, United States

  • Peking University Third Hospital

    Beijing, Beijing Municipality, 100000, China

  • Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310000, China

Conditions

Explore the condition pages connected to this study.